Lari Wenzel

picture of Lari  Wenzel

Professor, Medicine
School of Medicine

Professor
Public Health


Ph.D., Arizona State University, 1988, Counseling Psychology
M.S., University of Wisconsin, Madison, 1980, Rehabilitation Counseling Psychology
B.A., University of Wisconsin, Madison, 1978, Psychology

Phone: (949) 824-3926
Fax: (949) 824-3388
Email: lwenzel@uci.edu

University of California, Irvine
235 Irvine Hall
1001 Health Sciences Road
Mail Code: 3950
Irvine, CA 92697
Research Interests
Health-Related Quality of Life Outcomes, Patient-Reported Outcomes in Clinical Trials, Cancer Survivorship
Academic Distinctions
Who’s Who in Science and Engineering
Who's Who in American Women
Nominee, Who's Who in American Women
Outstanding Young Women of America Honor
Co-Chair, Patient-Centered Outcomes Research Committee, NRG Oncology
Publications
Wenzel L, Osann K, McKinney C, Cella D, Fulci G, Scroggins MJ, Lankes HA, Wang V, Nephew KP, Maxwell GL, Mok SC, Conrads TP, Miller A, Mannel RS, Gray HJ, Hanjani P, Huh WK, Spirtos N, Leitao Jr. MM, Glaser G, Sharma SK, Santin AD, Sperduto P, Lele SB, Burger RA, Monk BJ, Birrer M. Quality of life and adverse events: Prognostic relationships in long-term ovarian cancer survival. J Natl Cancer Inst. 2021;djab034. PMID: 33729494.
 
Wenzel L, Huang HQ, Cella D, McKinney C, Zevon M, LaChance J, Walker JL, Salani R, Modesitt SC, Morris R, Bradley WH, Boente MP, vonGruenigen VE. Patient-reported outcome changes at the end of life in recurrent platinum-resistant ovarian cancer: An NRG Oncology/Gynecologic Oncology Group Study. Gynecol Oncol. 2021.
 
Tucker JA, Osann K, Hsieh S, Wahi A, Monk BJ, Wenzel L, Nelson EL. Longitudinal changes in sleep: Associations with shifts in circulating cytokines and emotional distress in a cancer survivor population. Int J Behav Med. 2021;28(1):140-150. PMID: 33598780
 
Mai PL, Huang HQ, Wenzel LB, Han PK, Moser RP, Rodriguez GC, Boggess J, Rutherford TJ, Cohn DE, Kauff ND, Phillips KA, Wilkinson K, Wenham RM, Hamilton C, Powell MA, Walker JL, Greene MH, Hensley ML. Prospective follow-up of quality of life for participants undergoing risk-reducing salpingo-oophorectomy or ovarian cancer screening in GOG-0199: An NRG Oncology/GOG Study. Gynecol Oncol. 2019; S0090-8258(19):31613-31620. PMID: 31759774.
 
Carter J, Huang HQ, Armer J, Carlson JW, Lockwood S, Nolte S, Stewart BR, Kauderer J, Hutson A, Walker JL, Fleury AC, Bonebrake A, Soper JT, Mathews C, Zivanovic O, Richards WE, Tan A, Alberts DS, Barakat RR, Wenzel L. The Lymphedema and Gynecologic Cancer (LEG) study: the association between the Gynecologic cancer Lymphedema Questionnaire (GLCQ) and Lymphedema of the Lower Extremity (LLE). Gynecol Oncol. 2019; 155(3):452-460. PMID: 31679787.
 
Gil KM, Pugh SL, Klopp AH, Yeung AR, Wenzel L, Westin SN, Gaffney DK, Small W, Thompson S, Doncals DE, Cantuaria GHC, Yaremko BP, Chang A, Kundapur V, Mohan DS, Haas ML, Kim YB, Ferguson CL, Deshmukh S, Kachnic LA, Bruner DW. Expanded validation of the EPIC bowel and urinary domains for use in women with gynecologic cancer undergoing postoperative radiotherapy. Gynecol Oncol. 2019; 154(1):183-188. PMC: PMC6918674
 
Walker JL, Brady MF, Wenzel L, Fleming GF, Huang HQ, DiSilvestro PA, Fujiwara K, Alberts DS, Zheng W, Tewari, KS, Cohn DE, Powell MA, Le LV, Davidson SA, Gray HJ, Rose PG, Aghajanian C, Myers T, Secord AA, Rubin SC, Mannel RS. Randomized trial of intravenous versus intraperitoneal chemotherapy plus Bevacizumab in advanced ovarian carcinoma: An NRG Oncology/Gynecologic oncology group study. J Clin Oncol. 2019; 37(16):1380-1390. PMCID: PMC6544459.
 
Moss JL, Murphy J, Filiaci VL, Wenzel LB, Minasian L, Temkin SM. Disparities in health-related quality of life in women undergoing treatment for advanced ovarian cancer: the role of individual-level and contextual social determinants. Support Care Cancer. 2019; 27(2):531-538. PMCID: PMC6330149
 
von Gruenigen VE, Huang HQ, Cella D, Zevon M, LaChance JA, Walker JL, Salani R, Modesitt SC, Morris RT, Bradley WH, Boente MP, Wenzel L. Quality of life, symptoms and care needs in patients with persistent or recurrent platinum-resistant ovarian cancer: an NRG Oncology/Gynecologic Oncology Group Study. Gynecol Oncol. 2018; 150(1):119-126. PMID: 29778506
 
Klopp AH, Yeung AR, Deshmukh S, Gil KM, Wenzel L, Westin SN, Gifford K, Gaffney DK, Small W Jr, Thompson S, Doncals DE, Cantuaria GHC, Yaremko BP, Chang A, Kundapur V, Mohan DS, Haas ML, Kim YB, Ferguson CL, Pugh SL, Kachnic LA, Bruner DW. Patient-reported toxicity during pelvic intensity-modulated radiation therapy: NRG Oncology-RTOG 1203. J Clin Oncol. 2018; 36(24):2538-2544. PMCID: PMC6097832
 
Sisodia RC, Dewdney SB, Fader AN, Wethington SL, Melamed A, Von Gruenigen VE, Zivanovic O, Carter J, Cohn DE, Huh W, Wenzel L, Doll K, Cella D, Dowdy SC. Patient reported outcomes measures in gynecologic oncology: A primer for clinical use, part I. Gynecol Oncol. 2020;158(1):194-200. PMID: 32580886
 
Sisodia RC, Dewdney SB, Fader AN, Wethington SL, Melamed A, Von Gruenigen VE, Zivanovic O, Carter J, Cohn DE, Huh W, Wenzel L, Doll K, Cella D, Dowdy SC. Patient reported outcomes measures in gynecologic oncology: A primer for clinical use, part II. Gynecol Oncol. 2020;158(1):201-207. PMID: 32580887
 
Carter J, Huang HQ, Armer J, Carlson JW, Lockwood S, Nolte S, Kauderer J, Hutson A, Walker JL, Fleury AC, Bonebrake A, Soper JT, Mathews C, Zivanovic O, Richards WE, Tan A, Alberts DS, Barakat RR, Wenzel LB. GOG 244 - The Lymphedema and Gynecologic cancer (LeG) study: The impact of lower-extremity lymphedema on quality of life, psychological adjustment, physical disability, and function. Gynecol Oncol. 2021;160(1):244-251. PMCID: PMC7779696
 
Calvert M, King M, Mercieca-Bebber R, Aiyegbusi O, Kyte D, Slade A, Chan AW, Basch E, Bell J, Bennett A, Bhatnagar V, Blazeby J, Bottomley A, Brown J, Brundage M, Campbell L, Cappelleri JC, Draper H, Dueck AC, Ells C, Frank L, Golub RM, Griebsch I, Haywood K, Hunn A, King-Kallimanis B, Martin L, Mitchell S, Morel T, Nelson L, Norquist J, O'Connor D, Palmer M, Patrick D, Price G, Regnault A, Retzer A, Revicki D, Scott J, Stephens R, Turner G, Valakas A, Velikova G, von Hildebrand M, Walker A, Wenzel L. SPIRIT-PRO Extension explanation and elaboration: guidelines for inclusion of patient-reported outcomes in protocols of clinical trials. BMJ Open. 2021;11(6):e045105. PMCID: PMC8246371.
 
Gershenson D, Miller A, Brady W, Paul J, Carty K, Rodgers W, Millan D, Coleman R, Moore K, Banerjee S, Connolly K, Secord A, O’Malley D, Dorigo O, Gaillard S, Gabra H, Slomovitz B, Hanjani P, Farley J, Churchman M, Ewing A, Hollis R, Herrington S, Huang H, Wenzel L, Gourley C. Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): a randomized, open-label phase 2/3 trial. The Lancet. 2021.
 
Wenzel L, Mukamel D, Osann K, Havrilesky L, Sparks L, Lipscomb J, Wright AA, Walker J, Alvarez R, Van Le L, Robison K, Bristow R, Morgan R, Rimel BJ, Ladd H, Hsieh S, Wahi A, Cohn D. Rationale and study protocol for the Patient-Centered Outcome Aid (PCOA) randomized controlled trial: A personalized decision tool for newly diagnosed ovarian cancer patients. Contemporary Clinical Trials. 2017 (57): 29-36.
 
Wenzel L, Osann K, Hsieh S, Tucker J, Monk B, Nelson E. Psychosocial Telephone Counseling for Cervical Cancer Survivors: Results of a Randomized Biobehavioral Trial. Journal of Clinical Oncology. 33(10):1171-9. 2015 PMID: 25713429
 
Penson R, Huang H, Wenzel L, Monk B, Stockman S, Long H, Ramondetta L, Landrum L, Oaknin A, Reid T, Leitao M, Method M, Michael H, Tewari K. Bevacizumab for advanced cervical cancer: patient-reported outcomes of a randomised, phase 3 trial (NRG Oncology-Gynecologic Oncology Group protocol 240).Lancet Oncology. 16(3):301-11. 2015 PMID: 25638326
 
Wenzel L, Huang H, Cella D, Walker J, Armstrong D. Validation of FACT-GOG/AD Subscale for Ovarian Cancer Related Abdominal Discomfort: A Gynecologic Oncology Group Study. Gynecologic Oncology. 110(1):60–64 July 2008
 
Nelson E, Wenzel L, Osann K, Dogan Ates A, Chantana N, Reina-Patton A, Laust A, Nishimoto K, Chicz-DeMet A, du Pont N, Monk B. Stress, Immunity and Cervical Cancer: Biobehavioral Outcomes of a Randomized Clinical Trial. Clinical Cancer Research. 14(7):2111-18 April 1, 2008.
 
Wenzel L, Huang H, Armstrong D, Walker J, Cella D. Health-Related Quality of Life During and After Intraperitoneal Versus Intravenous Chemotherapy for Optimally Debulked Ovarian Cancer: A Gynecologic Oncology Group Study. Journal of Clinical Oncology. 25: 437-443, Feb 1 2007.
 
Armstrong D, Bundy B, Wenzel L, Huang H, Baergen R, Lele S, Copeland L, Walker J, Burger R. Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer: A GOG Study. New England Journal of Medicine. 354:34-43, Jan 5, 2006.
Grants
Genomic, Epigenomic and Psychosocial Characteristics of Long-Term Survivors of Ovarian Cancer. Department of Defense.
Disease-related Symptom Scale Validation in Recurrent Ovarian Cancer Phase III Studies GY004 and GY005. NCI’s Biomarker, Imaging, and Quality of Life Studies Funding Program (BIQSFP)
Professional Societies
American PsychoOncology Society
International PsychoOncology Society
American Society of Clinical Oncology
International Society of Quality of Life Research
Other Experience
Director, Biobehavioral Shared Resource
Chao Comprehensive Cancer Center, College of Medicine, University of California, Irvine

Research Center
Health Policy Research Institute
Last updated
10/07/2021